Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4% – Should You Sell?

Shares of Rapport Therapeutics (NASDAQ:RAPP) dropped 4% during trading on Tuesday . The stock traded as low as $17.60 and last traded at $17.75. Approximately 19,174 shares traded hands during trading, a decline of 87% from the average daily volume of 151,377 shares. The stock had previously closed at $18.49.

Rapport Therapeutics Stock Performance

The stock’s 50 day moving average price is $22.17.

Hedge Funds Weigh In On Rapport Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of RAPP. Values First Advisors Inc. bought a new position in Rapport Therapeutics during the third quarter valued at approximately $31,000. BNP Paribas Financial Markets purchased a new stake in Rapport Therapeutics in the third quarter worth about $34,000. JPMorgan Chase & Co. bought a new position in shares of Rapport Therapeutics in the third quarter worth about $83,000. SG Americas Securities LLC purchased a new position in shares of Rapport Therapeutics during the 3rd quarter valued at about $101,000. Finally, Sandia Investment Management LP bought a new stake in Rapport Therapeutics during the 2nd quarter worth approximately $116,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.